PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Report Buyer Ltd

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Cardiovascular Drug Blockbusters Under Pressure from Raft of Patent Expiries - Report Buyer, the online destination for business intelligence, has added a new report showing that growth in the use of cardiovascular drugs has been steady in the last five years at around three percent compound annual growth rate (CAGR) and growth
Cardiovascular Drug Blockbusters Under Pressure from Raft of Patent Expiries

 

NewswireToday - /newswire/ - London, United Kingdom, 2007/11/28 - Report Buyer, the online destination for business intelligence, has added a new report showing that growth in the use of cardiovascular drugs has been steady in the last five years at around three percent compound annual growth rate (CAGR) and growth.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

“Commercial Insight: Cardiovascular market overview” reports that despite growth in the use of cardiovascular drugs, sales growth is unlikely to match this. Growth in the last five years has been moderate at eight percent CAGR but there is likely to be negligible growth between now and 2016, giving an effective fall of three percent in cardiovascular revenues.

The report shows that sales growth is being hindered by the loss of patent protection on key cardiovascular blockbusters and the uptake of generic versions of leading drugs, as cost containment measures are promoted by national healthcare providers. Some of the brands losing patent protection during the 2010 to 2013 window include Pfizer’s Lipitor, the world’s number one selling brand, Sanofi Aventis/Bristol-Myers Squibb (BMS) Plavix, the best selling platelet aggregation inhibitor, and the anti-hypertensive, Novartis’ Diovan.

Authors of the report say the uptake of generic versions of these drugs is expected to be heavily promoted in an effort to reduce healthcare budgets and branded sales will slump accordingly. They note that replacement drugs currently in development are unlikely to be able to fill the void left by the loss of these blockbusters.

The report shows that many cardiovascular diseases now have an array of generic drugs that provide effective treatment without the need to resort to expensive branded products. This provides a major challenge to pharmaceutical companies as any new drug must be able to demonstrate significant clinical benefit to meet the cost effectiveness criteria determined by healthcare providers. According to the report, as a consequence, future blockbusters will not be of the same scale as the current crop. Byetta LAR is likely to be the best performing of the drugs currently in development and is predicted to have peak sales of $3 billion in the seven major markets. This compares to the sales of Lipitor in 2006 of $11.2 billion

However, the study shows that the one disease area which will continue to grow in the cardiovascular franchise is diabetes. With the majority of the western world in the grips of an obesity epidemic, the number of sufferers of type 2 diabetes will continue to increase at a rapid clip. Pharmaceutical companies have invested heavily in this area to meet unmet clinical needs and a large proportion of the top 10 cardiovascular brands in 2016 will be diabetes therapies.

The complex nature of insulin formulations and the lack of generic competition from biosimilar versions have safeguarded sales and margins of insulin products after the loss of patent protection. Biosimilar legislation which will provide marketing authorization for biosimilars is currently held up in both the US Congress and Senate as vested interests delay the approval of the bills.

The ‘patent cliff’ will be most acutely felt by Pfizer as patent protection in the US for Norvasc was lost in 2007 and Lipitor will be lost in 2010. Adding insult to injury, Pfizer’s current cardiovascular pipeline is particularly bare after the company dropped the development of the Lipitor replacement, torcetrapib, and the withdrawal of Exubera, an inhaled insulin which some analysts had predicted would generate $2 billion in annual sales but only generated $5 million in the US in the first half of 2007.

The report predicts revenue losses for many drug makers in the cardiovascular market once the ‘patent cliff’ takes effect. However, Pfizer will be acutely affected, with a net loss in cardiovascular revenue of $12 billion, with Sanofi-Aventis becoming the largest player in the cardiovascular market by 2009.

“Commercial Insight: Cardiovascular market overview” is available from Report Buyer. For more information visit the website.

Report Buyer product ID: DAT08267

About Report Buyer
Report Buyer is a UK-based independent online store supplying business information on major industry sectors. These include the Automotive Industry, Banking & Finance, Energy & Utilities, Food & Drink, Telecoms and Pharma & Healthcare. The website now carries over 40,000 business information products, including market reports, studies and books. Report Buyer is the intelligent way to buy market research making it an essential resource for executives and information buyers worldwide. Subscribers receive a free monthly newsletter and email alerts on new titles in their areas of interest. A regularly updated blog provides information on the latest market trends.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Report Buyer Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Cardiovascular Drug Blockbusters Under Pressure from Raft of Patent Expiries

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Jonna Dagliden 
+44 (0) 20 7060 7474 press[.]reportbuyer.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Report Buyer Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Report Buyer Ltd / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application
Genentech’s TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)